ELAB

Study identifies preliminary lean-mass finding at the highest EL-32 dose while informing future preclinical development strategy Results advance NorthStrive Biosciences' engineered probiotic platform targeting muscle preservation for patients on GLP-1 weight loss treatments NEWPORT BEACH, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”) today announced the completion of a preclinical study evaluating EL-32, an engineered probiotic candidate being developed by its wholly owned subsidiary, NorthStrive Biosciences Inc. (“NorthStrive”), both as a standalone treatment and in combination with semaglutide, the GLP-1 receptor agonist that is the active ingredient in Ozempic® and Wegovy®.

Adoption of NorthStrive® brand marks and DBA registration establishes a unified identify across PMGC's public holding company structure, with a formal legal name change expected within six months Adoption of NorthStrive® brand marks and DBA registration establishes a unified identify across PMGC's public holding company structure, with a formal legal name change expected within six months

PMGC's first sponsored SPAC adds a public-market acquisition vehicle to the holding company, targeting aerospace and defense, industrial technology, and critical supply chain manufacturers Sponsor position of approximately 2.7 million shares, or roughly 21.4% of NorthStrive Acquisition Corp I.'s Class A shares on an as-converted basis, aligns PMGC with value created through a future business combination NEWPORT BEACH, Calif.

Engagement of a leading global contract research organization strengthens the analytical foundation supporting EL-22 and EL-32 as the programs advance toward an IND-enabling development framework Builds on NorthStrive Biosciences' expanding manufacturing and characterization capabilities behind its engineered probiotic platform targeting muscle preservation, including for patients on GLP-1 weight loss treatments NEWPORT BEACH, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”) today announced that its subsidiary, NorthStrive Biosciences Inc. (“NorthStrive Biosciences” or “NorthStrive”), has executed a Statement of Work (“SOW”) with Charles River Laboratories, Inc., NYSE: CRL (“Charles River” or “Charles River Laboratories”) to conduct analytical characterization supporting the development of NorthStrive Biosciences' EL-22 and EL-32 engineered probiotic programs.

PMGC Holdings Inc. (Nasdaq: ELAB) Secures Five-Year Royalty Stream from Elevai Skincare Sale Under Executed Payment Agreement with Longevity Health Holdin

NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination

PMGC Holdings Terminates Previously Announced Acquisition LOI Following Due Diligence Review; Reaffirms Disciplined M&A Strategy and Expands Investment Acr

PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22

NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight

NEWPORT BEACH, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (“PMGC” or the “Company”) today announced that it will effect a 1-for-10 reverse stock split (the “Split”) of its issued and outstanding and authorized common stock, par value $0.0001 per share (“Common Stock”), effective at 12:00 am, Eastern time, on August 21, 2026.